IGEA Pharma NV
F:3B5
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/IC
Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.
Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.
Valuation Scenarios
If EV/IC returns to its Industry Average (0.9), the stock would be worth €-5.91 (135% downside from current price).
| Scenario | EV/IC Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -2.5 | €16.79 |
0%
|
| Industry Average | 0.9 | €-5.91 |
-135%
|
| Country Average | 1.2 | €-7.72 |
-146%
|
Forward EV/IC
Today’s price vs future invested capital
Peer Comparison
| Market Cap | EV/IC | P/E | ||||
|---|---|---|---|---|---|---|
| NL |
|
IGEA Pharma NV
F:3B5
|
505.5k EUR | -2.5 | 0.4 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
161.2B USD | 11 | 56.7 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
158.6B USD | 2.2 | 25 | |
| US |
|
Stryker Corp
NYSE:SYK
|
120.5B USD | 3.2 | 37.4 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
101.9B USD | 1.5 | 22.4 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
84.8B USD | 2.3 | 24 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
47.2B USD | 4.8 | 43.8 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
38.3B EUR | 1.2 | 18.6 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
44.1B USD | 14.7 | 42.2 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
41.4B USD | 1.2 | 24 | |
| US |
|
Resmed Inc
NYSE:RMD
|
30.9B USD | 4.4 | 20.9 |
Market Distribution
| Min | 0 |
| 30th Percentile | 0.8 |
| Median | 1.2 |
| 70th Percentile | 1.9 |
| Max | 36 345.7 |
Other Multiples
IGEA Pharma NV
Glance View
IGEA Pharma NV is a health-tech company focused on measure and control of test factors related to life-threatening diseases. The company is headquartered in Hoofddorp, Noord-Holland. The company went IPO on 2018-12-20. The firm focuses on research and development of biomedical solutions for the prevention of diabetes and Alzheimer's disease. Its offering portfolio includes medical testing devices and dietary supplements. The firm develops ALZ-1 Test, a blood test to measure and control level of free copper, also known as Free Copper II or Non-Ceruloplasmin Copper in the bloodstream, which is a major recognized modifiable risk factor for the Alzheimer’s disease. The firm offers its services in the Netherlands.
